CollectionsEli Lilly
IN THE NEWS

Eli Lilly

FEATURED ARTICLES
BUSINESS
January 31, 2009 | By Miriam Hill INQUIRER STAFF WRITER
Eli Lilly & Co. pleaded guilty yesterday to a criminal count of illegally marketing its powerful antipsychotic drug, Zyprexa, in a settlement that the federal government said would "send a message to Eli Lilly employees that they need to respect the law, not break it. " The guilty plea in federal court in Philadelphia had been expected since earlier this month, when the Indianapolis company agreed to a settlement that also included a $1.4 billion...
NEWS
August 7, 2008 | By Damian Troise and Tom Murphy, ASSOCIATED PRESS
INDIANAPOLIS - Drug-development services company Covance Inc. will buy an Indiana research center from Eli Lilly and Co. and enter a 10-year service deal with the drugmaker worth $1.6 billion. New Jersey-based Covance will pay $50 million for Lilly's 450-acre drug development campus in Greenfield, Ind., while offering employment to about 260 Lilly employees. Lilly is headquartered in Indianapolis. Covance will use the site to provide mostly early-stage clinical trial work to Lilly as part of the 10-year contract.
BUSINESS
July 17, 1992 | By Donna Shaw, INQUIRER STAFF WRITER
Centocor Inc. has turned to Eli Lilly & Co. for marketing muscle and cash, effectively abandoning its long-held goal of going it alone to commercialize its flagship product. The two companies announced yesterday that Lilly would market and sell Centoxin, an antibacterial drug, and provide up to $125 million to the Malvern biotechnology company. With Lilly handling marketing for and sales of Centoxin, Centocor will be free to concentrate on development, manufacturing and regulatory approvals, the companies said in a joint statement.
NEWS
January 27, 2009 | By Laurie Magid
Martha is a widow who lives near her family and is sometimes confused or agitated. Many of us have a Martha in our lives - a mother, grandmother or older friend who surely does not suffer from schizophrenia or bipolar disorder, but who may, at times, have behavioral issues or symptoms of anxiety, depression or dementia. "Martha" was one of the fictitious patients highlighted in the sales brochures of pharmaceutical giant Eli Lilly & Co. as a model patient for its drug Zyprexa. From 1999 to 2005, as part of a calculated, aggressive marketing campaign, Lilly deployed an army of sales representatives across the country to market Zyprexa for uses that the Food and Drug Administration never approved as safe and effective.
BUSINESS
January 4, 2016 | By David Sell, Staff Writer
Injectable insulin, which keeps some diabetics alive and keeps others out of serious health crises, has soared in price in the last few years. "It is out of control," said Carol Hammond, 72, a diabetic who lives in North Philadelphia and survives on Social Security. "My rent isn't too bad, but after paying for insulin, I don't have much left. " Hammond said she skips buying or taking doses because her Medicare and Medicare Advantage health- insurance plans don't always cover the cost of her insulin at the pharmacy counter.
BUSINESS
January 14, 2016 | By Harold Brubaker, STAFF WRITER
Tmunity Therapeutics Inc., a Philadelphia company founded last year to build on research at the University of Pennsylvania's Center for Cellular Immunotherapies, said it received a $10 million investment from Penn Medicine and Lilly Asia Ventures, an affiliate of drugmaker Eli Lilly & Co. Gene therapy pioneer Carl June, who has led Penn's immunotherapy trials for more than two decades, cofounded Tmunity, which is working on therapies that enable...
BUSINESS
April 7, 1990 | Inquirer photographs by Michael Mally
At the Wharton School, MBA students make sport of themselves yearly for a good cause: adult literacy. This year they hoped to raise $26,000 from the two-day Wharton Olympics, which reached a climax yesterday with outdoor events such as the "Corporate Rat Race" and the "Brown Nose Relay. " Their hopes were buoyed by pre-Olympic pledges of $18,000 from major corporate sponsors, including Eli Lilly & Co., Ford, Goldman Sachs and Marakon Associates.
BUSINESS
February 12, 2016 | By Linda Loyd, STAFF WRITER
TransCelerate BioPharma Inc., a King of Prussia-based nonprofit organization that aims to find quicker and more efficient ways of producing new medicines, said Wednesday it was launching a subsidiary, BioCelerate, to improve efficiencies in preclinical research. Six pharmaceutical companies will be founding members of BioCelerate. The first initiative will be sharing toxicity data in preclinical studies, according to TransCelerate CEO Dalvir Gill. The six member drugmakers are: Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly & Co., GlaxoSmithKline, Novo Nordisk, and Shionogi & Co. lloyd@phillynews.com 215-854-2831 @LoydLinda  
BUSINESS
April 23, 1986 | By Gilbert M. Gaul and James Asher, Inquirer Staff Writers
Records of SmithKline Beckman Corp. have been subpoenaed by a federal grand jury in Philadelphia in an investigation into possible price-fixing by the makers of certain antibiotics used in hospitals. Jeremy Heymsfeld, a spokesman for SmithKline, yesterday confirmed that numerous documents had been turned over to federal investigators. But he declined to specifiy the nature of the records, when the subpoena was received or whether SmithKline was considered a target of the probe.
NEWS
August 2, 1991 | By Gregory Spears, Inquirer Washington Bureau
The government has rejected claims that the widely prescribed antidepressant Prozac caused violent mood swings that could lead to suicide or murderous rage, and it will allow the drug to remain on the market. "The data and information available at this time do not indicate Prozac causes suicidality or violent behavior," the Food and Drug Administration concluded in an opinion released yesterday. Prozac, the world's largest-selling antidepressant, is taken by more than two million Americans, according to its maker, Eli Lilly and Co. of Indianapolis.
1 | 2 | 3 | 4 | 5 | Next »
ARTICLES BY DATE
BUSINESS
February 12, 2016 | By Linda Loyd, STAFF WRITER
TransCelerate BioPharma Inc., a King of Prussia-based nonprofit organization that aims to find quicker and more efficient ways of producing new medicines, said Wednesday it was launching a subsidiary, BioCelerate, to improve efficiencies in preclinical research. Six pharmaceutical companies will be founding members of BioCelerate. The first initiative will be sharing toxicity data in preclinical studies, according to TransCelerate CEO Dalvir Gill. The six member drugmakers are: Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly & Co., GlaxoSmithKline, Novo Nordisk, and Shionogi & Co. lloyd@phillynews.com 215-854-2831 @LoydLinda  
BUSINESS
January 14, 2016 | By Harold Brubaker, STAFF WRITER
Tmunity Therapeutics Inc., a Philadelphia company founded last year to build on research at the University of Pennsylvania's Center for Cellular Immunotherapies, said it received a $10 million investment from Penn Medicine and Lilly Asia Ventures, an affiliate of drugmaker Eli Lilly & Co. Gene therapy pioneer Carl June, who has led Penn's immunotherapy trials for more than two decades, cofounded Tmunity, which is working on therapies that enable...
BUSINESS
January 13, 2016
In the Region Penn Medicine funds drug firm Tmunity Therapeutics Inc. , a Philadelphia company founded last year to build on research at the University of Pennsylvania's Center for Cellular Immunotherapies, said it received a $10 million investment from Penn Medicine and Lilly Asia Ventures , an affiliate of drugmaker Eli Lilly & Co . Gene therapy pioneer Carl June, who has led Penn's immunotherapy trials for more than two decades, cofounded...
BUSINESS
January 4, 2016 | By David Sell, Staff Writer
Injectable insulin, which keeps some diabetics alive and keeps others out of serious health crises, has soared in price in the last few years. "It is out of control," said Carol Hammond, 72, a diabetic who lives in North Philadelphia and survives on Social Security. "My rent isn't too bad, but after paying for insulin, I don't have much left. " Hammond said she skips buying or taking doses because her Medicare and Medicare Advantage health- insurance plans don't always cover the cost of her insulin at the pharmacy counter.
BUSINESS
June 4, 2015 | By Jacob Adelman, Inquirer Staff Writer
The University City Science Center plans to more than double its size over 10 years as it seeks to lure higher-profile biomedical and technology firms to the West Philadelphia business incubation and research complex. The Science Center and its development partner on the expansion, Wexford Science & Technology, will pool their landholdings in the area to build more than four million square feet of offices, laboratories, homes, retail shops, and parking structures, the Science Center said Tuesday.
BUSINESS
April 24, 2014 | By David Sell, Inquirer Staff Writer
In a multibillion-dollar deal, drugmakers GlaxoSmithKline and Novartis said Tuesday that they would trade parts of their companies and form a joint venture with a third part. GSK, based in London and with several facilities in the Philadelphia region, will sell its current cancer drugs to Swiss-based Novartis for $16 billion. Novartis will sell all but one of its vaccines to GSK for about $7.1 billion. The companies formed a joint venture to sell over-the-counter medicine, with GSK taking a 63.5 percent stake.
BUSINESS
October 21, 2013 | By Linda Loyd, Inquirer Staff Writer
Shares of ViroPharma Inc., a drugmaker with headquarters in Exton that specializes in medicines for rare diseases, soared after recent reports that the European pharmaceutical companies Sanofi and Shire P.L.C. might be interested in buying the company. ViroPharma stock closed Sept. 17 at a 13-year high of $40.78. Since then, some analysts say, it has become unclear whether the buyout will happen. "A deal would make sense, but it's still speculative," said Akiva Felt, biotechnology analyst with Oppenheimer & Co. in San Francisco.
BUSINESS
July 11, 2013 | By David Sell, Inquirer Staff Writer
Finding a cure for Alzheimer's disease remains a dream for patients suffering from the debilitating brain condition, family members struggling to help them, and pharmaceutical companies hoping to make billions of dollars treating them. But there is no consensus on even the best direction of research, and that uncertainty has affected a Philadelphia subsidiary of Eli Lilly & Co., Avid Radiopharmaceuticals. The Centers for Medicare and Medicaid (CMS) said last week that it probably would not pay for as many of the diagnostic tests Lilly hoped it would when the drug giant bought Avid in 2010.
BUSINESS
July 1, 2013
Daniel M. Skovronsky, M.D., Ph.D . Age: 39. Title: President, CEO, Avid Radiopharmaceuticals Inc. Number of Employees: About 100. Tenure: Founded the molecular imaging agent company in December 2004. Financials: In 2010, Eli Lilly & Co. bought Avid for up to $800 million if benchmarks were met. Diagnosing Alzheimer's: More than 100 years ago, Dr. Alois Alzheimer [the discoverer of Alzheimer's disease] had a patient with dementia. After she died, he looked at her brain under the microscope and discovered it was full of these things called amyloid plaques.
BUSINESS
May 8, 2013 | By David Sell, Inquirer Staff Writer
The drugmaker Pfizer Inc. said Monday that it would begin selling its erectile dysfunction drug Viagra online in hopes of thwarting counterfeit Web-only pharmacies, holding off legitimate competitors, and boosting profits. The pharmaceutical industry will watch this closely because it could change how drugs are bought, paid for, and delivered through the many layers of the current and complicated system. Pfizer will market the drug through viagra.com, but CVS Caremark will handle the online processing and shipping.
1 | 2 | 3 | 4 | 5 | Next »
|
|
|
|
|